Research On The Quality Of Environmental Accounting Information Disclosure Of Listed Pharmaceutical Companie

As people become more aware of environmental protection,environmental issues have become one of the most important topics on a global scale.President Xi Jinping proposed in his 2022 speech to the two sessions that "achieving the ’double carbon’ goal is a broad and profound change and a long-term task that must be both determined and promoted in a scientific and orderly manner." As the main source of environmental pollution,heavily polluting enterprises are obliged to take responsibility for environmental protection.As one of the heavily polluting industries,the pharmaceutical industry has industry-specific pollution emissions,and expired drugs and residual antibiotics in waste residues can cause great harm to the environment.Therefore,it is imperative to study the disclosure of environmental accounting information in the pharmaceutical industry,which is crucial to promote the green and low-carbon transformation of the pharmaceutical industry and help China achieve its dual-carbon goal as soon as possible.Based on information asymmetry theory,sustainable development theory and stakeholder theory,this thesis combines relevant domestic and international literature to study the quality of environmental accounting information disclosure of listed companies in the pharmaceutical industry in China.First,the environmental accounting information disclosure carriers and contents of 165 listed companies in pharmaceutical industry from 2017-2021 are analyzed and problems are pointed out.In order to further quantitatively evaluate the disclosure quality of environmental accounting information in the pharmaceutical industry,this thesis refers to the environmental indicators in the latest documents and the self-constructed ESG rating framework of various authoritative institutions,combines the industry characteristics of the pharmaceutical industry,refers to the quality requirements of information disclosure in the GRI guidelines and the ESG Report Rating Standard for Chinese Enterprises(2023),and evaluates the disclosure quality from the completeness,balance,comprehensibility,timeliness,and The evaluation indexes are designed in the dimensions of completeness,balance,comprehensibility,timeliness and reliability,and the indexes of "typical air pollutant emissions during the production of APIs or intermediates" and "resource utilization of pharmaceutical waste" are added to the evaluation system established by current scholars,and the hierarchical analysis method is applied to determine the weight of each index.The evaluation system of environmental accounting information disclosure quality in pharmaceutical industry is completed by applying hierarchical analysis to determine the weight of each indicator.The evaluation system was then applied to the case company,Jiangzhong Pharmaceuticals,to evaluate the disclosure quality of Jiangzhong Pharmaceuticals,and Baiyunshan and Yunnan Baiyao were selected for cross-sectional comparison with the case company.It was found that:(1)The environmental accounting information disclosure of Jiangzhong Pharmaceuticals was scattered and irregular in form,which affected the comparability of information.(2)The disclosure interval of each report is long,which makes the timeliness of the information lacking.(3)The disclosure of environmental financial information is not comprehensive enough,which hinders the integrity of the information.(4)The graphical visualization of environmental information disclosure is low,and the comprehensibility of the information needs to be improved.(5)Due to the lack of internal and external audits,the reliability of environmental accounting information disclosure in Jiangzhong is somewhat problematic.Finally,in response to the problems found in the study,suggestions for improvement are made at the macro,meso and micro levels for the state,industry and pharmaceutical companies at different levels.